360 related articles for article (PubMed ID: 27200298)
1. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC.
Bansal P; Osman D; Gan GN; Simon GR; Boumber Y
Front Oncol; 2016; 6():112. PubMed ID: 27200298
[TBL] [Abstract][Full Text] [Related]
2. Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Zer A; Leighl N
Front Oncol; 2014; 4():329. PubMed ID: 25505733
[TBL] [Abstract][Full Text] [Related]
3. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
4. Beyond
Farago AF; Azzoli CG
Transl Lung Cancer Res; 2017 Oct; 6(5):550-559. PubMed ID: 29114471
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
König D; Savic Prince S; Rothschild SI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33671873
[TBL] [Abstract][Full Text] [Related]
6. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives.
Genova C; Rossi G; Tagliamento M; Rijavec E; Biello F; Cerbone L; Zullo L; Grossi F
Expert Rev Respir Med; 2020 Apr; 14(4):367-383. PubMed ID: 31917616
[No Abstract] [Full Text] [Related]
8. Clinicopathological characteristics of
Dugay F; Llamas-Gutierrez F; Gournay M; Medane S; Mazet F; Chiforeanu DC; Becker E; Lamy R; Léna H; Rioux-Leclercq N; Belaud-Rotureau MA; Cabillic F
Oncotarget; 2017 Aug; 8(32):53336-53351. PubMed ID: 28881815
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapies for Lung Cancer.
Stinchcombe TE
Cancer Treat Res; 2016; 170():165-82. PubMed ID: 27535394
[TBL] [Abstract][Full Text] [Related]
10. New horizons for uncommon mutations in non-small cell lung cancer:
Olmedo ME; Cervera R; Cabezon-Gutierrez L; Lage Y; Corral de la Fuente E; Gómez Rueda A; Mielgo-Rubio X; Trujillo JC; Couñago F
World J Clin Oncol; 2022 Apr; 13(4):276-286. PubMed ID: 35582653
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy for NSCLC with driver mutations.
Minuti G; D'Incecco A; Cappuzzo F
Expert Opin Biol Ther; 2013 Oct; 13(10):1401-12. PubMed ID: 23930754
[TBL] [Abstract][Full Text] [Related]
12. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.
Pietrantonio F; Di Nicolantonio F; Schrock AB; Lee J; Tejpar S; Sartore-Bianchi A; Hechtman JF; Christiansen J; Novara L; Tebbutt N; Fucà G; Antoniotti C; Kim ST; Murphy D; Berenato R; Morano F; Sun J; Min B; Stephens PJ; Chen M; Lazzari L; Miller VA; Shoemaker R; Amatu A; Milione M; Ross JS; Siena S; Bardelli A; Ali SM; Falcone A; de Braud F; Cremolini C
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29370427
[TBL] [Abstract][Full Text] [Related]
13. Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.
Giustini NP; Jeong AR; Buturla J; Bazhenova L
Clin Chest Med; 2020 Jun; 41(2):223-235. PubMed ID: 32402358
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK.
Rothschild SI
Cancers (Basel); 2015 May; 7(2):930-49. PubMed ID: 26018876
[TBL] [Abstract][Full Text] [Related]
15. Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer.
Guo Y; Cao R; Zhang X; Huang L; Sun L; Zhao J; Ma J; Han C
Onco Targets Ther; 2019; 12():10343-10360. PubMed ID: 31819518
[TBL] [Abstract][Full Text] [Related]
16. Beyond Conventional: The New Horizon of Targeted Therapy for the Treatment of Advanced Non Small Cell Lung Cancer.
Tartarone A; Lapadula V; Di Micco C; Rossi G; Ottanelli C; Marini A; Giorgione R; Ferrari K; Catalano M; Voltolini L; Mini E; Roviello G
Front Oncol; 2021; 11():632256. PubMed ID: 34094913
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: An effort to explore new drug targets.
Veldore VH; Patil S; Satheesh CT; Shashidhara HP; Tejaswi R; Prabhudesai SA; Krishnamoorthy N; Hazarika D; Naik R; Rao RM; Ajai Kumar BS
Indian J Cancer; 2015; 52(2):243-8. PubMed ID: 26853422
[TBL] [Abstract][Full Text] [Related]
19. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
